新型冠状病毒肺炎的爆发需要病毒疫苗。
The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines.
作者信息
Shang Weilong, Yang Yi, Rao Yifan, Rao Xiancai
机构信息
Department of Microbiology, College of Basic Medical Sciences, Army Medical University (Third Military Medical University), 400038 Chongqing, China.
出版信息
NPJ Vaccines. 2020 Mar 6;5(1):18. doi: 10.1038/s41541-020-0170-0. eCollection 2020.
Abstract
The outbreak of 2019-novel coronavirus disease (COVID-19) that is caused by SARS-CoV-2 has spread rapidly in China, and has developed to be a Public Health Emergency of International Concern. However, no specific antiviral treatments or vaccines are available yet. This work aims to share strategies and candidate antigens to develop safe and effective vaccines against SARS-CoV-2.
摘要
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019新型冠状病毒病（COVID-19）疫情已在中国迅速蔓延，并已发展成为一场国际关注的突发公共卫生事件。然而，目前尚无特异性抗病毒治疗方法或疫苗。这项工作旨在分享开发针对SARS-CoV-2的安全有效疫苗的策略和候选抗原。
相似文献
1
The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines.新型冠状病毒肺炎的爆发需要病毒疫苗。
NPJ Vaccines. 2020 Mar 6;5(1):18. doi: 10.1038/s41541-020-0170-0. eCollection 2020.
2
Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection.针对 SARS-CoV-2 感染的抗病毒药物和疫苗研发中的治疗策略。
Mol Neurobiol. 2020 Nov;57(11):4856-4877. doi: 10.1007/s12035-020-02074-2. Epub 2020 Aug 18.
3
The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.新型严重急性呼吸系统综合症冠状病毒 2（SARS-CoV-2）的爆发：当前全球状况综述。
J Infect Public Health. 2020 Nov;13(11):1601-1610. doi: 10.1016/j.jiph.2020.07.011. Epub 2020 Aug 4.
4
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病（COVID-19）疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
5
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.2020 年大流行：当前 SARS-CoV-2 疫苗的开发。
Front Immunol. 2020 Aug 19;11:1880. doi: 10.3389/fimmu.2020.01880. eCollection 2020.
6
Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.SARS-CoV-2 感染的分子机制与分子治疗。
Curr Mol Med. 2022;22(7):621-639. doi: 10.2174/1566524021666211013121831.
7
An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.关于在疫情爆发情况下治疗新型冠状病毒（SARS-CoV-2）的新兴治疗和预防策略的循证系统评价。
J Basic Clin Physiol Pharmacol. 2020 Sep 14;31(6):jbcpp-2020-0113. doi: 10.1515/jbcpp-2020-0113.
8
The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment.新型冠状病毒（SARS-CoV-2）爆发的前 75 天：最新进展、预防和治疗。
Int J Environ Res Public Health. 2020 Mar 30;17(7):2323. doi: 10.3390/ijerph17072323.
9
Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.抗击 COVID-19：诊断、治疗和疫苗的快速回顾。
Biomed J. 2020 Aug;43(4):341-354. doi: 10.1016/j.bj.2020.05.021. Epub 2020 May 30.
10
The novel zoonotic COVID-19 pandemic: An expected global health concern.新型人畜共患的新冠疫情：一个意料之中的全球卫生问题。
J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671.
引用本文的文献
1
Comprehensive and translational pathobiology of COVID-19 based on cellular and molecular techniques.基于细胞和分子技术的新冠病毒综合与转化病理生物学
Pract Lab Med. 2025 Aug 11;46:e00497. doi: 10.1016/j.plabm.2025.e00497. eCollection 2025 Sep.
2
Impact of SARS-CoV-2 on Aerobic and Anaerobic Capacity in Professional Ice Hockey Players.严重急性呼吸综合征冠状病毒2对职业冰球运动员有氧和无氧能力的影响。
J Clin Med. 2025 May 16;14(10):3478. doi: 10.3390/jcm14103478.
3
RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2.展示RBD的外膜囊泡纳米疫苗增强对SARS-CoV-2的免疫力。
J Nanobiotechnology. 2025 Feb 8;23(1):97. doi: 10.1186/s12951-025-03191-7.
4
Physicochemical properties-based hybrid machine learning technique for the prediction of SARS-CoV-2 T-cell epitopes as vaccine targets.基于物理化学性质的混合机器学习技术用于预测作为疫苗靶点的SARS-CoV-2 T细胞表位
PeerJ Comput Sci. 2024 Apr 25;10:e1980. doi: 10.7717/peerj-cs.1980. eCollection 2024.
5
Enhancing explainable SARS-CoV-2 vaccine development leveraging bee colony optimised Bi-LSTM, Bi-GRU models and bioinformatic analysis.利用蜜蜂群体优化的 Bi-LSTM、Bi-GRU 模型和生物信息学分析增强 SARS-CoV-2 疫苗的可解释性开发。
Sci Rep. 2024 Mar 20;14(1):6737. doi: 10.1038/s41598-024-55762-7.
6
Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants.利用免疫脂质体作为针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其新出现变体的纳米载体。
Asian J Pharm Sci. 2023 Nov;18(6):100855. doi: 10.1016/j.ajps.2023.100855. Epub 2023 Oct 20.
7
Independent Protection and Influence of the Spike-Specific Antibody Response of SARS-CoV-2 Nucleocapsid Protein (N) in Whole-Virion Vaccines.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）核衣壳蛋白（N）的刺突特异性抗体反应在全病毒疫苗中的独立保护作用及影响
Vaccines (Basel). 2023 Nov 2;11(11):1681. doi: 10.3390/vaccines11111681.
8
CoVigator-A Knowledge Base for Navigating SARS-CoV-2 Genomic Variants.CoVigator- 用于导航 SARS-CoV-2 基因组变异的知识库。
Viruses. 2023 Jun 17;15(6):1391. doi: 10.3390/v15061391.
9
Potential of Lactoferrin in the Treatment of Lung Diseases.乳铁蛋白在肺部疾病治疗中的潜力。
Pharmaceuticals (Basel). 2023 Jan 28;16(2):192. doi: 10.3390/ph16020192.
10
Development of SARS-CoV-2 Vaccine: Challenges and Prospects.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的研发：挑战与前景
Diseases. 2023 Apr 20;11(2):64. doi: 10.3390/diseases11020064.
本文引用的文献
1
Protocol for Prevention and Control of COVID-19 (Edition 6).新型冠状病毒肺炎防控方案（第六版）
China CDC Wkly. 2020 May 8;2(19):321-326. doi: 10.46234/ccdcw2020.082.
2
Pre- and Posttreatment Chest CT Findings: 2019 Novel Coronavirus (2019-nCoV) Pneumonia.治疗前和治疗后胸部CT表现：2019新型冠状病毒（2019-nCoV）肺炎
Radiology. 2020 Apr;295(1):21. doi: 10.1148/radiol.2020200323. Epub 2020 Feb 12.
3
A new coronavirus associated with human respiratory disease in China.一种在中国与人类呼吸道疾病相关的新型冠状病毒。
Nature. 2020 Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3. Epub 2020 Feb 3.
4
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
5
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.新型冠状病毒受体识别：基于 SARS 冠状病毒长达十年结构研究的分析。
J Virol. 2020 Mar 17;94(7). doi: 10.1128/JVI.00127-20.
6
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.新型冠状病毒感染肺炎在中国武汉的早期传播动力学。
N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
7
Return of the Coronavirus: 2019-nCoV.冠状病毒再现：2019-nCoV。
Viruses. 2020 Jan 24;12(2):135. doi: 10.3390/v12020135.
8
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.从武汉旅行回来后出现非典型肺炎症状的患者身上分离出的 2019 年新型人致病冠状病毒的基因组特征。
Emerg Microbes Infect. 2020 Jan 28;9(1):221-236. doi: 10.1080/22221751.2020.1719902. eCollection 2020.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
Coronavirus envelope protein: current knowledge.冠状病毒包膜蛋白：当前的认识。
Virol J. 2019 May 27;16(1):69. doi: 10.1186/s12985-019-1182-0.
Zotero 插件